NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

ORCL gains on strong cloud momentum, while NVO battles obesity headwinds and LIN leans on $10B backlog for growth.

SINGAPORE—China is racing toward economic self-sufficiency by weaning itself off American technology. But it has made a ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Shares of Virgin Galactic (NYSE:SPCE) surged 10% in premarket trading, while Rocket Lab (NASDAQ:RKLB) rose 3.5%, and Boeing (NYSE:BA) saw a modest 0.5% uptick. The movement comes after an analyst ...

Citi analysts have maintained their 2025 semiconductor sales forecast of an 8% year-over-year increase, despite April sales falling below seasonal expectations.